KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Capital Expenditures (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 12 years of Capital Expenditures data on record, last reported at $4.0 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 784.11% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.9 million, up 839.96%, while the annual FY2025 figure was $4.7 million, 796.75% up from the prior year.
  • Capital Expenditures reached $4.0 million in Q4 2025 per ACAD's latest filing, up from $388000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $4.0 million in Q4 2025 and bottomed at $1000.0 in Q4 2021.
  • Average Capital Expenditures over 3 years is $862571.4, with a median of $388000.0 recorded in 2025.
  • Peak YoY movement for Capital Expenditures: tumbled 99.95% in 2021, then soared 784.11% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $1000.0 in 2021, then surged by 45200.0% to $453000.0 in 2024, then soared by 784.11% to $4.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $4.0 million in Q4 2025, $388000.0 in Q3 2025, and $453000.0 in Q4 2024.